Woo-Jeong Sim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Woo-Jeong Sim has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Ah-Yeon Lee
Department of Medical Information, School of Nursing and Health, Kongju National University, 32588 Kongju, Republic of Korea
5 shared publications - Gyeong-U Hong
Department of Medical Information, School of Nursing and Health, Kongju National University, 32588 Kongju, Republic of Korea
5 shared publications - Ji-Eun An
College of Pharmacy, Kangwon National University, Chuncheon-si, Republic of Korea
5 shared publications - Min Ju Kim
Department of Medical Information, School of Nursing and Health, Kongju National University, 32588 Kongju, Republic of Korea
5 shared publications - Soo Hyun Lee
Department of Medical Information, School of Nursing and Health, Kongju National University, 32588 Kongju, Republic of Korea
5 shared publications - Su-Yeon Yu
College of Pharmacy, Kangwon National University, Chuncheon, Republic of Korea
5 shared publications
Latest Publications
- Open Access
- 24 July 2026
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
Validity of HINT-8 in evaluating health-related quality of life among cervical cancer patients
Aim: Cervical cancer, caused primarily by human papillomavirus infection, affects patients' health-related quality of life (HRQoL). Despite research on quality of life in cancer patients, studies using the HINT-8 instrument, especially for cervical cancer, are scarce. This study evaluates the validity of HINT-8 in measuring HRQoL among Korean cervical cancer patients by comparing it with EQ-5D-5L. Materials & methods: Demographic and clinical characteristics were analyzed. Mean, median and standard deviations for each domain of both instruments were calculated. Spearman and Pearson correlation coefficients assessed relationships between HINT-8 and EQ-5D-5L indices and domains. Results: Increased problem intensity in HINT-8 domains (e.g., stair climbing, pain and vitality) was correlated with decreased EQ-5D-5L index, indicating a higher response level in HINT-8 aligns with lower EQ-5D-5L scores. Significant variables were consistent across tools, showing no substantial functional difference. A strong correlation between HINT-8 and EQ-5D-5L indices (r = 0.771, p < 0.01) supports HINT-8’s effectiveness in evaluating HRQoL for cervical cancer patients. Conclusion: The HINT-8 demonstrated a strong correlation with the EQ-5D-5L index and a substantially lower ceiling effect, suggesting that it can capture subtle differences in HRQoL among cervical cancer patients. Furthermore, the HINT-8 may provide complementary information beyond the EQ-5D-5L by capturing distinct dimensions such as memory, sleep and happiness, which are not explicitly represented in the EQ-5D-5L descriptive system. These findings support the validity of the HINT-8 as a complementary instrument for assessing HRQoL in Korean cervical cancer patients.
- 24 July 2026
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
Open AccessValidity of HINT-8 in evaluating health-related quality of life among cervical cancer patients
Aim: Cervical cancer, caused primarily by human papillomavirus infection, affects patients' health-related quality of life (HRQoL). Despite research on quality of life in cancer patients, studies using the HINT-8 instrument, especially for cervical cancer, are scarce. This study evaluates the validity of HINT-8 in measuring HRQoL among Korean cervical cancer patients by comparing it with EQ-5D-5L. Materials & methods: Demographic and clinical characteristics were analyzed. Mean, median and standard deviations for each domain of both instruments were calculated. Spearman and Pearson correlation coefficients assessed relationships between HINT-8 and EQ-5D-5L indices and domains. Results: Increased problem intensity in HINT-8 domains (e.g., stair climbing, pain and vitality) was correlated with decreased EQ-5D-5L index, indicating a higher response level in HINT-8 aligns with lower EQ-5D-5L scores. Significant variables were consistent across tools, showing no substantial functional difference. A strong correlation between HINT-8 and EQ-5D-5L indices (r = 0.771, p < 0.01) supports HINT-8’s effectiveness in evaluating HRQoL for cervical cancer patients. Conclusion: The HINT-8 demonstrated a strong correlation with the EQ-5D-5L index and a substantially lower ceiling effect, suggesting that it can capture subtle differences in HRQoL among cervical cancer patients. Furthermore, the HINT-8 may provide complementary information beyond the EQ-5D-5L by capturing distinct dimensions such as memory, sleep and happiness, which are not explicitly represented in the EQ-5D-5L descriptive system. These findings support the validity of the HINT-8 as a complementary instrument for assessing HRQoL in Korean cervical cancer patients.
- Open Access
- 27 May 2026
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 27 (5)
Indirect Treatment Comparison of Riociguat Replacement Therapy and Selexipag Add-on Therapy in Patients With Pulmonary Arterial Hypertension: Results From a Systematic Review
Background: Despite standard combination therapy with endothelin receptor antagonists (ERAs) and phosphodiesterase-5 inhibitors (PDE5is), many patients with pulmonary arterial hypertension (PAH) show inadequate therapeutic responses. Riociguat (a soluble guanylate cyclase stimulator) and selexipag (a prostacyclin receptor agonist) are both approved as next-step therapies; however, their comparative effectiveness and safety remain unknown due to the lack of head-to-head trials. We aimed to compare the therapeutic effects of riociguat replacement and selexipag add-on therapy through an indirect treatment comparison. Methods: Randomized controlled trials (RCTs) involving patients with PAH receiving either riociguat or selexipag were identified through a systematic search of PubMed, EMBASE, and the Cochrane Library up to 04 November 2025. This systematic review adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guideline. Study quality was assessed with Cochrane's Risk of Bias 2.0 tool. Indirect treatment comparisons using Bucher's method were conducted within a common comparator (ERA + PDE5i) framework. Results: Three RCTs (four publications) were included: REPLACE, GRIPHON (main and post-hoc analyses), and a phase II trial. The overall risk of bias was low, except for the phase II trial, which had unclear risk due to its small sample size. Indirect comparisons showed no significant differences between the therapies for any outcome. The hazard ratio for clinical worsening was 0.167 (95% confidence interval [CI]: 0.0019–1.495, p = 0.1066). Mean differences for 6-min walk distance and N-terminal pro–B-type natriuretic peptide were 10.64 m (95% CI: –9.158 to 30.438, p = 0.2920) and –46.62 pg/mL (95% CI: –307.826 to 214.586, p = 0.7263). The relative risk of overall adverse events was 1.07 (95% CI: 0.90–1.27, p = 0.453). Subgroup analyses of patients receiving baseline ERA + PDE5i therapy and those classified as World Health Organization functional class III also showed no significant differences. Conclusions: We found no significant differences between riociguat replacement and selexipag add-on therapy. These findings provide comparative data to help clinicians and patients make informed treatment decisions. Further head-to-head trials are needed to confirm comparative effectiveness. This review adhered to PRISMA 2020 guidelines. The PROSPERO Registration: CRD42024524391 https://www.crd.york.ac.uk/PROSPERO/view/CRD42024524391.
- 27 May 2026
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 27 (5)
Open AccessIndirect Treatment Comparison of Riociguat Replacement Therapy and Selexipag Add-on Therapy in Patients With Pulmonary Arterial Hypertension: Results From a Systematic Review
Background: Despite standard combination therapy with endothelin receptor antagonists (ERAs) and phosphodiesterase-5 inhibitors (PDE5is), many patients with pulmonary arterial hypertension (PAH) show inadequate therapeutic responses. Riociguat (a soluble guanylate cyclase stimulator) and selexipag (a prostacyclin receptor agonist) are both approved as next-step therapies; however, their comparative effectiveness and safety remain unknown due to the lack of head-to-head trials. We aimed to compare the therapeutic effects of riociguat replacement and selexipag add-on therapy through an indirect treatment comparison. Methods: Randomized controlled trials (RCTs) involving patients with PAH receiving either riociguat or selexipag were identified through a systematic search of PubMed, EMBASE, and the Cochrane Library up to 04 November 2025. This systematic review adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guideline. Study quality was assessed with Cochrane's Risk of Bias 2.0 tool. Indirect treatment comparisons using Bucher's method were conducted within a common comparator (ERA + PDE5i) framework. Results: Three RCTs (four publications) were included: REPLACE, GRIPHON (main and post-hoc analyses), and a phase II trial. The overall risk of bias was low, except for the phase II trial, which had unclear risk due to its small sample size. Indirect comparisons showed no significant differences between the therapies for any outcome. The hazard ratio for clinical worsening was 0.167 (95% confidence interval [CI]: 0.0019–1.495, p = 0.1066). Mean differences for 6-min walk distance and N-terminal pro–B-type natriuretic peptide were 10.64 m (95% CI: –9.158 to 30.438, p = 0.2920) and –46.62 pg/mL (95% CI: –307.826 to 214.586, p = 0.7263). The relative risk of overall adverse events was 1.07 (95% CI: 0.90–1.27, p = 0.453). Subgroup analyses of patients receiving baseline ERA + PDE5i therapy and those classified as World Health Organization functional class III also showed no significant differences. Conclusions: We found no significant differences between riociguat replacement and selexipag add-on therapy. These findings provide comparative data to help clinicians and patients make informed treatment decisions. Further head-to-head trials are needed to confirm comparative effectiveness. This review adhered to PRISMA 2020 guidelines. The PROSPERO Registration: CRD42024524391 https://www.crd.york.ac.uk/PROSPERO/view/CRD42024524391.
- Open Access
- 27 May 2026
- Vol. 27 (5)
Indirect Treatment Comparison of Riociguat Replacement Therapy and Selexipag Add-on Therapy in Patients With Pulmonary Arterial Hypertension: Results From a Systematic Review
Despite standard combination therapy with endothelin receptor antagonists (ERAs) and phosphodiesterase-5 inhibitors (PDE5is), many patients with pulmonary arterial hypertension (PAH) show inadequate therapeutic responses. Riociguat (a soluble guanylate cyclase stimulator) and selexipag (a prostacyclin receptor agonist) are both approved as next-step therapies; however, their comparative effectiveness and safety remain unknown due to the lack of head-to-head trials. We aimed to compare the therapeutic effects of riociguat replacement and selexipag add-on therapy through an indirect treatment comparison. Randomized controlled trials (RCTs) involving patients with PAH receiving either riociguat or selexipag were identified through a systematic search of PubMed, EMBASE, and the Cochrane Library up to 04 November 2025. This systematic review adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guideline. Study quality was assessed with Cochrane's Risk of Bias 2.0 tool. Indirect treatment comparisons using Bucher's method were conducted within a common comparator (ERA + PDE5i) framework. Three RCTs (four publications) were included: REPLACE, GRIPHON (main and post-hoc analyses), and a phase II trial. The overall risk of bias was low, except for the phase II trial, which had unclear risk due to its small sample size. Indirect comparisons showed no significant differences between the therapies for any outcome. The hazard ratio for clinical worsening was 0.167 (95% confidence interval [CI]: 0.0019–1.495, p = 0.1066). Mean differences for 6-min walk distance and N-terminal pro–B-type natriuretic peptide were 10.64 m (95% CI: –9.158 to 30.438, p = 0.2920) and –46.62 pg/mL (95% CI: –307.826 to 214.586, p = 0.7263). The relative risk of overall adverse events was 1.07 (95% CI: 0.90–1.27, p = 0.453). Subgroup analyses of patients receiving baseline ERA + PDE5i therapy and those classified as World Health Organization functional class III also showed no significant differences. We found no significant differences between riociguat replacement and selexipag add-on therapy. These findings provide comparative data to help clinicians and patients make informed treatment decisions. Further head-to-head trials are needed to confirm comparative effectiveness. This review adhered to PRISMA 2020 guidelines. CRD42024524391 https://www.crd.york.ac.uk/PROSPERO/view/CRD42024524391.
- 27 May 2026
- Vol. 27 (5)
Open AccessIndirect Treatment Comparison of Riociguat Replacement Therapy and Selexipag Add-on Therapy in Patients With Pulmonary Arterial Hypertension: Results From a Systematic Review
Despite standard combination therapy with endothelin receptor antagonists (ERAs) and phosphodiesterase-5 inhibitors (PDE5is), many patients with pulmonary arterial hypertension (PAH) show inadequate therapeutic responses. Riociguat (a soluble guanylate cyclase stimulator) and selexipag (a prostacyclin receptor agonist) are both approved as next-step therapies; however, their comparative effectiveness and safety remain unknown due to the lack of head-to-head trials. We aimed to compare the therapeutic effects of riociguat replacement and selexipag add-on therapy through an indirect treatment comparison. Randomized controlled trials (RCTs) involving patients with PAH receiving either riociguat or selexipag were identified through a systematic search of PubMed, EMBASE, and the Cochrane Library up to 04 November 2025. This systematic review adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guideline. Study quality was assessed with Cochrane's Risk of Bias 2.0 tool. Indirect treatment comparisons using Bucher's method were conducted within a common comparator (ERA + PDE5i) framework. Three RCTs (four publications) were included: REPLACE, GRIPHON (main and post-hoc analyses), and a phase II trial. The overall risk of bias was low, except for the phase II trial, which had unclear risk due to its small sample size. Indirect comparisons showed no significant differences between the therapies for any outcome. The hazard ratio for clinical worsening was 0.167 (95% confidence interval [CI]: 0.0019–1.495, p = 0.1066). Mean differences for 6-min walk distance and N-terminal pro–B-type natriuretic peptide were 10.64 m (95% CI: –9.158 to 30.438, p = 0.2920) and –46.62 pg/mL (95% CI: –307.826 to 214.586, p = 0.7263). The relative risk of overall adverse events was 1.07 (95% CI: 0.90–1.27, p = 0.453). Subgroup analyses of patients receiving baseline ERA + PDE5i therapy and those classified as World Health Organization functional class III also showed no significant differences. We found no significant differences between riociguat replacement and selexipag add-on therapy. These findings provide comparative data to help clinicians and patients make informed treatment decisions. Further head-to-head trials are needed to confirm comparative effectiveness. This review adhered to PRISMA 2020 guidelines. CRD42024524391 https://www.crd.york.ac.uk/PROSPERO/view/CRD42024524391.
- Open Access
- 27 April 2026
- Published by Springer Nature in BMC Women's Health
- Vol. 26 (1)
Factors affecting health-related quality of life in cervical cancer survivors: a multicenter cross-sectional study in Korea
Cervical cancer is the fourth most common malignancy among women worldwide. As survival rates continue to improve with advances in early detection and trea
- 27 April 2026
- Published by Springer Nature in BMC Women's Health
- Vol. 26 (1)
Open AccessFactors affecting health-related quality of life in cervical cancer survivors: a multicenter cross-sectional study in Korea
Cervical cancer is the fourth most common malignancy among women worldwide. As survival rates continue to improve with advances in early detection and trea
- Open Access
- 16 October 2025
- Published by Springer Nature in Health and Quality of Life Outcomes
- Vol. 23 (1) , 1-10
Validation of the health-related quality of life instrument with 8 items for assessing health-related quality of life in patients with oropharyngeal cancer: a comparison with the EQ-5D-5L
To overcome the limitations of existing health-related quality of life (HRQoL) instruments, the HRQoL Instrument with 8 Items (HINT-8) was developed for the Korean population. We aimed to evaluate the validity, interrater reliability, and agreement of the HINT-8 compared to the EQ-5D-5 L among patients with oropharyngeal cancer (OPC). A total of 327 patients with OPC aged ≥ 19 years who received treatment at 14 hospitals in South Korea were recruited between August 2023 and February 2024. HRQoL was assessed using the two instruments. The psychometric evaluation included analyses of validity (convergent and known-group validity), agreement (intraclass correlation coefficient and Bland–Altman analysis), and reliability (internal consistency measured by Cronbach’s alpha). The ceiling effects and score distributions were also examined. In total, 299 respondents were included in the final analysis. Both instruments demonstrated high internal consistency (HINT-8: α = 0.872; EQ-5D-5 L: α = 0.845) and good agreement (intraclass correlation coefficient [ICC] = 0.80; 95% confidence interval [CI]: 0.76–0.84). The convergent validity was supported by strong correlations between the HINT-8 index and both the EQ-5D-5 L index (r = 0.805) and EQ VAS (r = 0.715). The ceiling effect of HINT-8 (12.7%) was substantially lower than the EQ-5D-5 L (32.8%). The HINT-8 is a valid, reliable, and responsive instrument for measuring HRQoL in patients with oropharyngeal cancer. These findings suggest that HINT-8 can serve as a valuable complementary instrument to the EQ-5D-5 L.
- 16 October 2025
- Published by Springer Nature in Health and Quality of Life Outcomes
- Vol. 23 (1) , 1-10
Open AccessValidation of the health-related quality of life instrument with 8 items for assessing health-related quality of life in patients with oropharyngeal cancer: a comparison with the EQ-5D-5L
To overcome the limitations of existing health-related quality of life (HRQoL) instruments, the HRQoL Instrument with 8 Items (HINT-8) was developed for the Korean population. We aimed to evaluate the validity, interrater reliability, and agreement of the HINT-8 compared to the EQ-5D-5 L among patients with oropharyngeal cancer (OPC). A total of 327 patients with OPC aged ≥ 19 years who received treatment at 14 hospitals in South Korea were recruited between August 2023 and February 2024. HRQoL was assessed using the two instruments. The psychometric evaluation included analyses of validity (convergent and known-group validity), agreement (intraclass correlation coefficient and Bland–Altman analysis), and reliability (internal consistency measured by Cronbach’s alpha). The ceiling effects and score distributions were also examined. In total, 299 respondents were included in the final analysis. Both instruments demonstrated high internal consistency (HINT-8: α = 0.872; EQ-5D-5 L: α = 0.845) and good agreement (intraclass correlation coefficient [ICC] = 0.80; 95% confidence interval [CI]: 0.76–0.84). The convergent validity was supported by strong correlations between the HINT-8 index and both the EQ-5D-5 L index (r = 0.805) and EQ VAS (r = 0.715). The ceiling effect of HINT-8 (12.7%) was substantially lower than the EQ-5D-5 L (32.8%). The HINT-8 is a valid, reliable, and responsive instrument for measuring HRQoL in patients with oropharyngeal cancer. These findings suggest that HINT-8 can serve as a valuable complementary instrument to the EQ-5D-5 L.